DC-AdGMCAIX / Gilead - LARVOL DELTA

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - P1; N=12; Completed; Sponsor: Jonsson Comprehensive Cancer Center; Active, not recruiting ➔ Completed

Trial completion • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CA9

A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. (PubMed, J Immunother) - "These early data show that autologous immature DC-AdGMCAIX can be safely given to metastatic RCC patients without any serious adverse events with CAIX-specific immune response elicited by the treatment. These preliminary data support further study of Ad-GMCAIX, particularly with combination therapies that may enhance clinical activity."

Clinical • Journal • Fatigue • Genito-urinary Cancer • Hematological Disorders • Leukopenia • Oncology • Renal Cell Carcinoma • Solid Tumor • CA9

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - P1; N=12; Active, not recruiting; Sponsor: Jonsson Comprehensive Cancer Center; Trial completion date: Jan 2020 ➔ Jan 2022; Trial primary completion date: Dec 2019 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • CA9

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - P1; N=12; Active, not recruiting; Sponsor: Jonsson Comprehensive Cancer Center; Trial primary completion date: Dec 2018 ➔ Dec 2019

Clinical • Trial primary completion date